Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Monalizumab, Anti-NKG2A
IPH2201 · 2 trials · 2 indications
To confirm the recommended phase II dose (RP2D) of single agent IPH2201 in patients with advanced/metastatic/recurrent platinum sensitive or resistant high-grade serous carcinoma (HGSC) of ovarian, fallopian tube or peritoneal origin.
To assess the occurrence of Drug Limited Toxicities (DLTs)
rate of patients in complete or partial response according to RECIST 1.1.
| Arm | Type | Description |
|---|---|---|
| IPH2201 | EXPERIMENTAL | Part 1: 1, 4 or 10mg/kg, IV, 1 hour duration on Day 1 every 2 weeks. Part 2: Patients will receive single agent IPH2201 as above with the actual dose dependent on the outcome of Part 1 |
| Dose escalation | EXPERIMENTAL | Dose escalation of monalizumab in combination with cetuximab |
| Expansion cohort 1 | EXPERIMENTAL | monalizumab + cetuximab expansion cohort |
| Expansion cohort 2 | EXPERIMENTAL | monalizumab + cetuximab expansion cohort in patients with prior exposure to PD-(L)1 blockers |
| Expansion cohort 3 | EXPERIMENTAL | monalizumab + cetuximab + anti-PD(L)1 |
| Name | Type | Description |
|---|---|---|
| IPH2201 | DRUG | - |
| Monalizumab | BIOLOGICAL | - |
| Cetuximab | BIOLOGICAL | - |
| Anti-PD(L)1 | BIOLOGICAL | - |
Inclusion Criteria: * Patients must have a histologically and/or cytologically confirmed gynecologic malignancy including high-grade serous ovarian/fallopian tube or peritoneal carcinoma, cervical cancer (squamous cell carcinoma) or endometrial cancer (adenocarcinoma), that is advanced/metastatic/r...
IPH2201 is an investigational monoclonal antibody being studied in gynecologic cancer. It was evaluated in a Phase 1 dose-ranging study in patients with gynecologic malignancies. It is not approved for any indication and remains in clinical development.
IPH2201 is being developed by Innate Pharma S.A., which trades under the ticker IPHA. The company sponsored the Phase 1 dose-ranging study of IPH2201 in patients with gynecologic malignancies.
IPH2201 is in Phase 1 clinical development. Its single trial, a dose-ranging study in gynecologic malignancies, has been completed. The drug is investigational and has not been approved for any indication.
IPH2201 has been studied in one clinical trial, NCT02459301, titled A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies. The Phase 1 trial enrolled 59 female patients aged 18 years and older in Canada and is completed.
No. IPH2201 is an investigational monoclonal antibody in Phase 1 development and has not been approved for any indication. Its only clinical trial, a completed Phase 1 dose-ranging study in gynecologic malignancies, evaluated the drug in 59 patients.